The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma
Open accessAbstract
Purpose: To determine whether density and distribution of tumor-infiltrating lymphocytes (TILs; TIL grade) is an independent predictor of sentinel lymph node (SLN) status and survival in patients with clinically localized primary cutaneous melanoma. Methods: From the Melanoma Institute Australia database, 1,865 patients with a single primary melanoma ≥ 0.75 mm in thickness were identified. The associations of clinical and pathologic factors with SLN status, recurrence-free survival (RFS), and melanoma-specific survival (MSS) were analyzed. Results: The majority of patients had either no (TIL grade 0; 35.4%) or few (TIL grade 1; 45.1%) TILs, with a minority showing moderate (TIL grade 2; 16.3%) or marked (TIL grade 3; 3.2%) TILs. Tumor thickness, mitotic rate, and Clark level were inversely correlated with TIL grade (each P < .001). SLN biopsy was performed in 1,138 patients (61.0%) and was positive in 252 (22.1%). There was a significant inverse association between SLN status and TIL grade (SLN positivity rates for each TIL grade: 0, 27.8%; 1, 20.1%; 2, 18.3%; 3, 5.6%; P < .001). Predictors of SLN positivity were decreasing age (P < .001), decreasing TIL grade (P < .001), ulceration (P = .003), increasing tumor thickness (P = .01), satellitosis (P = .03), and increasing mitoses (P = .03). The 5-year MSS and RFS rates were 83% and 76%, respectively (median follow-up, 43 months). Tumor thickness (P < .001), ulceration (P < .001), satellitosis (P < .001), mitotic rate (P = .003), TIL grade (P < .001), and sex (P = .01) were independent predictors of MSS. Patients with TIL grade 3 tumors had 100% survival. Conclusion: TIL grade is an independent predictor of survival and SLN status in patients with melanoma. Patients with a pronounced TIL infiltrate have an excellent prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Self-citationFinal Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
Balch, C. M., Buzaid, A. C., Soong, S.-J., Atkins, M. B., Cascinelli, N., Coit, D. G., Fleming, I. D., Gershenwald, J. E., Houghton, A., Kirkwood, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3635 · Cited by 2,636
Self-citationRosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812223192527 · Cited by 2,389
Balch, C. M., Soong, S.-J., Gershenwald, J. E., Thompson, J. F., Reintgen, D. S., Cascinelli, N., Urist, M., McMasters, K. M., Ross, M. I., Kirkwood, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3622 · Cited by 2,388
Self-citationSentinel-Node Biopsy or Nodal Observation in Melanoma
Morton, D. L., Thompson, J. F., Cochran, A. J., Mozzillo, N., Elashoff, R., Essner, R., Nieweg, O. E., Roses, D. F., Hoekstra, H. J., Karakousis, C. P., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060992 · Cited by 1,824
Self-citationModel Predicting Survival in Stage I Melanoma Based on Tumor Progression
Clark, W. H., Elder, D. E., Guerry, D., Braitman, L. E., Trock, B. J., Schultz, D., Synnestvedt, M., & Halpern, A. C. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.24.1893 · Cited by 1,247
Clemente, C. G., Mihm, M. C., Bufalino, R., Zurrida, S., Collini, P., & Cascinelli, N. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1303::aid-cncr12>3.0.co;2-5 · Cited by 1,171
HUMAN T CELL RESPONSES AGAINST MELANOMA
Boon, T., Coulie, P. G., Eynde, B. J. V. D., & Bruggen, P. V. D. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090733 · Cited by 651
Regulation of the T cell response
Romagnani, S. (2006) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2006.02606.x · Cited by 401
Bogunovic, D., O'Neill, D. W., Belitskaya-Levy, I., Vacic, V., Yu, Y.-L., Adams, S., Darvishian, F., Berman, R., Shapiro, R., Pavlick, A. C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905139106 · Cited by 384
Thompson, J. F., Soong, S.-J., Balch, C. M., Gershenwald, J. E., Ding, S., Coit, D. G., Flaherty, K. T., Gimotty, P. A., Johnson, T., Johnson, M. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.5812 · Cited by 363
Self-citationMihm, M. C., Clemente, C. G., & Cascinelli, N. (1996) · PubMed · Cited by 318
CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
Dudley, M. E., Gross, C. A., Langhan, M. M., Garcia, M. R., Sherry, R. M., Yang, J. C., Phan, G. Q., Kammula, U. S., Hughes, M. S., Citrin, D. E., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1297 · Cited by 315
Taylor, R. C., Patel, A., Panageas, K. S., Busam, K. J., & Brady, M. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9755 · Cited by 297
Predicting five-year outcome for patients with cutaneous melanoma in a population-based study
Barnhill, R. L., Fine, J. A., Roush, G. C., & Berwick, M. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960801)78:3<427::aid-cncr8>3.0.co;2-g · Cited by 296
Hirahara, K., Liu, L., Clark, R. A., Yamanaka, K.-I., Fuhlbrigge, R. C., & Kupper, T. S. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4488 · Cited by 291
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.
Oble, D. A., Loewe, R. P., Yu, P., & Mihm, M. C. (2009) · PubMed · Cited by 207
Francken, A. B., Shaw, H. M., Thompson, J. F., Soong, S.-J., Accortt, N. A., Azzola, M. F., Scolyer, R. A., Milton, G. W., McCarthy, W. H., Colman, M. H., et al. (2004) · Annals of Surgical Oncology · doi:10.1245/aso.2004.07.014 · Cited by 196
Self-citationInflammatory chemokines in cancer growth and progression
Rollins, B. J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.002 · Cited by 195
Gimotty, P. A., Van Belle, P., Elder, D. E., Murry, T., Montone, K. T., Xu, X., Hotz, S., Raines, S., Ming, M. E., Wahl, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.0735 · Cited by 175
Itzhaki, O., Hovav, E., Ziporen, Y., Levy, D., Kubi, A., Zikich, D., Hershkovitz, L., Treves, A. J., Shalmon, B., Zippel, D., et al. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318209c94c · Cited by 169
Interobserver Reproducibility of Histopathologic Prognostic Variables in Primary Cutaneous Melanomas
Scolyer, R. A., Shaw, H. M., Thompson, J. F., et al. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200312000-00011 · Cited by 168
Self-citationCutaneous melanoma in the era of molecular profiling
Thompson, J. F., Scolyer, R. A., & Kefford, R. F. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61397-0 · Cited by 146
Self-citationvan Houdt, I. S., Sluijter, B. J. R., Moesbergen, L. M., Vos, W., de Gruijl, T. D., Molenkamp, B. G., van den Eertwegh, A. J. M., Hooijberg, E., van Leeuwen, P. A. M., Meijer, C. J. L. M., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23543 · Cited by 138
Hillen, F., Baeten, C. I. M., van de Winkel, A., Creytens, D., van der Schaft, D. W. J., Winnepenninckx, V. J. L., & Griffioen, A. W. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0353-9 · Cited by 126
Fatal attraction: tumors beckon regulatory T cells
Shevach, E. M. (2004) · Nature Medicine · doi:10.1038/nm0904-900 · Cited by 121
Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma
Kruper, L. L., Spitz, F. R., Czerniecki, B. J., Fraker, D. L., Blackwood‐Chirchir, A., Ming, M. E., Elder, D. E., Elenitsas, R., Guerry, D., & Gimotty, P. A. (2006) · Cancer · doi:10.1002/cncr.22295 · Cited by 115
Risk Assessment in Localized Primary Cutaneous Melanoma
Tuthill, R. J., Unger, J. M., Liu, P. Y., Flaherty, L. E., & Sondak, V. K. (2002) · American Journal of Clinical Pathology · doi:10.1309/wbf7-n8kh-71kt-rvq9 · Cited by 108
Li, Y., Liu, S., Hernandez, J., Vence, L. M., Hwu, P., & Radvanyi, L. G. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901101 · Cited by 97
Mandalà, M., Imberti, G. L., Piazzalunga, D., Belfiglio, M., Labianca, R., Barberis, M. C. P., Marchesi, L., Poletti, P. L., Bonomi, L., Novellino, L., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.05.034 · Cited by 92
Prognostic Significance of Tumor Infiltrating Lymphocytes in Melanoma
Burton, A. L., Roach, B. A., Mays, M. P., Chen, A. F., Ginter, B., Vierling, A. M., Scoggins, C. R., Martin, R. C. G., Stromberg, A. J., Hagendoorn, L. J., et al. (2011) · The American Surgeon · doi:10.1177/000313481107700219 · Cited by 92
Weber, J. S., Atkins, M. B., Hwu, P., Radvanyi, L. G., Sznol, M., & Yee, C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2272 · Cited by 87
Chapon, M., Randriamampita, C., Maubec, E., Badoual, C., Fouquet, S., Wang, S.-F., Marinho, E., Farhi, D., Garcette, M., Jacobelli, S., et al. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.30 · Cited by 86
Expansion and Characterization of Human Melanoma Tumor-Infiltrating Lymphocytes (TILs)
Nguyen, L. T., Yen, P. H., Nie, J., Liadis, N., Ghazarian, D., Al‐Habeeb, A., Easson, A. M., Leong, W. L., Lipa, J. E., McCready, D. R., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013940 · Cited by 57
Larsen, T. E., & Grude, T. H. (1978) · PubMed · Cited by 42
Cited by
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
Self-citationTaube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Tertiary lymphoid structures in cancer
Schumacher, T. N., & Thommen, D. S. (2022) · Science · doi:10.1126/science.abf9419 · Cited by 1,142
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells
Jansen, C. S., Prokhnevska, N., Master, V. A., Sanda, M. G., Carlisle, J. W., Bilen, M. A., Cardenas, M., Wilkinson, S., Lake, R., Sowalsky, A. G., et al. (2019) · Nature · doi:10.1038/s41586-019-1836-5 · Cited by 817
Metadata
- Authors
- Azimi, F., Scolyer, R. A., Rumcheva, P., Moncrieff, M., Murali, R., McCarthy, S. W., Saw, R. P., & Thompson, J. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-07-20
- Volume
- 30
- Issue
- 21
- Pages
- 2678-2683
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2150770343
- Cited by
- 856
- References
- 36
- FWCI
- 13.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.